Skip to main content
Livermore
Livermore
ZHEN

Black Diamond Therapeutics, Inc.

BDTX
Exchange
Nasdaq
Industry
Biological Products, (No Diagnostic Substances)
SEC CIK
0001701541

No open-market purchases or sales by Black Diamond Therapeutics, Inc. insiders were filed in the last 90 days; 96 institutions reported holding it in 13F filings for Q2 2026, worth $64.9M in total; no superinvestor holds it.

Holders of 5% or more of BDTX

Holders whose latest Schedule 13D or 13G filing reports 5% or more of Black Diamond Therapeutics, Inc., largest stake first. The change is against the holder's previous filing.

Holders of 5% or more of BDTX
HolderLatest formStakeChangeFirst filedLatest filingFiling
BlackRock, Inc.13G6.70%3.84M shares+2.20 ppfrom 4.50%Apr 29, 20252 filingsJul 27, 2026SEC

Stakes are as of each holder's latest filing. Holders whose last filing was in the old format (before December 18, 2024) have no stake on record and are not listed, and after an acquisition or delisting holders usually stop filing.

13D and 13G filings

5 Schedule 13D and 13G filings on Black Diamond Therapeutics, Inc., newest first, including old-format filings without a stake.

Schedule 13D and 13G filings on BDTX
Filed (ET)FilerFormStakeChangeEvent dateFiling
Jul 27, 20264:25 PM ETBlackRock, Inc.13G6.70%3.84M shares+2.20 ppfrom 4.50%Jun 30, 2026SEC
Feb 17, 20264:09 PM ETVestal Point Capital, LPand 1 other13G/A1.50%870.0K shares–Below 5%Dec 31, 2025SEC
Apr 29, 20258:03 AM ETBlackRock, Inc.13G/A4.50%2.52M shares–Below 5%Mar 31, 2025SEC
Mar 21, 20251:01 PM ETBB Biotech AGand 1 other13G/A4.80%2.73M shares−10.30 ppfrom 15.10%Below 5%Mar 19, 2025SEC
Feb 14, 20252:36 PM ETBB Biotech AGand 1 other13G/A15.10%8.52M shares–Dec 31, 2024SEC

Form 144: proposed insider sales

Notices from officers, directors and other affiliates planning to sell Black Diamond Therapeutics, Inc. shares.

No Form 144 notices for Black Diamond Therapeutics, Inc. are on file.